What it's for (Indications)
- Labetalol is a dual alpha- and beta-adrenergic receptor blocker indicated for the management of hypertension.
- Its oral formulation is used for chronic hypertension, contributing to sustained blood pressure reduction.
- The intravenous formulation is primarily reserved for acute severe hypertension, including hypertensive emergencies where rapid and controlled blood pressure reduction is critical, such as in preeclampsia/eclampsia, perioperative hypertension, or other conditions requiring urgent blood pressure management.
- This therapeutic agent helps to mitigate the risks associated with elevated blood pressure, thereby preventing target organ damage and improving cardiovascular outcomes.
- Its efficacy in various hypertensive states underscores its utility in diverse clinical settings.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for labetalol vary significantly depending on the route of administration, patient's clinical condition, and response to therapy. For oral hypertension management, typical initial adult doses range from 100 mg twice daily, which can be titrated upwards at intervals of 2-3 days based on blood pressure response and tolerability, with maintenance doses often ranging from 200 mg to 400 mg twice daily, not exceeding 2400 mg per day. For intravenous administration in hypertensive emergencies, an initial bolus of 20 mg is commonly administered over two minutes. Subsequent doses of 40 mg or 80 mg may be given at 10-minute intervals until desired blood pressure control is achieved or a maximum cumulative dose of 300 mg is reached. Alternatively, a continuous intravenous infusion can be initiated at 2 mg per minute and adjusted according to blood pressure response. Dosage adjustments are crucial in patients with hepatic impairment or those on concomitant medications. |
Safety & Warnings
Common Side Effects
- Labetalol, like other antihypertensive agents, is associated with a range of potential side effects, which can vary in severity and incidence.
- Common adverse reactions reported include dizziness, fatigue, nausea, vomiting, dyspepsia, and headache.
- Orthostatic hypotension, characterized by a sudden drop in blood pressure upon standing, is also frequently observed, particularly after the initial dose or dose titration, due to its alpha-1 blocking properties.
- More serious, albeit less common, side effects can involve the respiratory system, leading to bronchospasm, especially in susceptible individuals.
- Cardiovascular effects may include bradycardia, heart block, and worsening of heart failure symptoms.
- Hepatic injury, including cholestatic jaundice, has been reported rarely.
- Central nervous system effects can include lethargy, depression, and sleep disturbances.
- Patients should be advised to report any persistent or severe side effects to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Labetalol does not carry a specific Black Box Warning from the U.S. Food and Drug Administration (FDA). However, several serious warnings and precautions are critically important for safe and effective use, necessitating careful consideration by healthcare professionals. **Serious Warnings:** 1. **Cardiac Failure and Ischemic Heart Disease:** In patients with congestive heart failure, continued depression of the myocardium by beta-blocking agents can precipitate more severe failure. Labetalol should be used with caution in such patients. Abrupt withdrawal of beta-blockers in patients with coronary artery disease can exacerbate angina pectoris, precipitate myocardial infarction, or ventricular arrhythmias. Therefore, discontinuation should be gradual over 1-2 weeks. 2. **Bronchospastic Disease:** Labetalol is contraindicated in bronchial asthma and other bronchospastic conditions due to the risk of severe bronchoconstriction from non-selective beta-blockade. Even in patients without a history of asthma, caution is advised in those with non-allergic bronchospasm or emphysema. 3. **Pheochromocytoma:** While labetalol has both alpha- and beta-blocking properties, its use in pheochromocytoma requires careful evaluation. Paradoxical hypertension has been reported in patients with pheochromocytoma receiving beta-blockers alone. It is generally recommended that alpha-blockade be established prior to beta-blockade in these patients. 4. **Hepatic Injury:** Severe hepatocellular injury, including fatal cases, has been reported rarely. Routine liver function monitoring is recommended, and labetalol should be discontinued if liver enzyme elevations or jaundice occurs. 5. **Anaphylactic Reactions:** Patients with a history of severe anaphylactic reactions to various allergens may be more reactive to repeated challenge while taking beta-blockers. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. 6. **Diabetes and Hypoglycemia:** Beta-blockers may mask important manifestations of hypoglycemia, particularly tachycardia, in diabetic patients. They may also potentiate insulin-induced hypoglycemia.
- Labetalol should be used with extreme caution in patients with underlying conditions that could be exacerbated by its pharmacological actions.
- Patients with compensated heart failure require careful monitoring as beta-blockade can depress myocardial contractility and precipitate more severe cardiac failure; initiation should be at low doses with gradual titration.
- Bronchospastic diseases, such as asthma or chronic obstructive pulmonary disease (COPD), are significant concerns, as labetalol's non-selective beta-2 blockade can induce bronchoconstriction.
- In diabetic patients, labetalol may mask symptoms of hypoglycemia, such as tachycardia, and careful monitoring of blood glucose levels is essential.
- Abrupt discontinuation of labetalol, particularly in patients with ischemic heart disease, can lead to exacerbation of angina, myocardial infarction, or ventricular arrhythmias; therefore, withdrawal should be gradual over 1-2 weeks.
- Use in pheochromocytoma requires careful alpha-blockade before beta-blockade to avoid paradoxical hypertension.
- Caution is also advised in patients with liver impairment due to altered metabolism.
How it Works (Mechanism of Action)
Labetalol exerts its antihypertensive effects through a unique dual mechanism involving both selective alpha-1 adrenergic receptor blockade and non-selective beta-1 and beta-2 adrenergic receptor blockade. The alpha-1 blockade leads to peripheral vasodilation, reducing total peripheral resistance without a significant reflex tachycardia, a common response seen with pure vasodilators, due to its concurrent beta-blockade. The non-selective beta-blockade reduces heart rate, myocardial contractility, and cardiac output. This combined action results in a decrease in systemic blood pressure through both a reduction in peripheral vascular resistance and a decrease in cardiac output. Additionally, labetalol partially blocks the release of renin from the kidneys, further contributing to its hypotensive effect. Its unique pharmacological profile allows for effective blood pressure control while maintaining cerebral blood flow, making it particularly useful in various hypertensive settings.
Commercial Brands (Alternatives)
No other brands found for this formula.